Radiotherapy for Early-Stage Breast Cancer
(H-ASSIST Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study evaluates the rates of radiation-specific toxicity, quality of life, and oncologic outcomes for early-stage breast cancer and ductal carcinoma in situ treated with 5-fraction whole breast irradiation (WBI) with a simultaneous integrated tumor bed boost (SIB). SIB refers to the technique tumor bed boost given at the same time as standard radiation therapy.The FAST-Forward trial previously showed that a 1-week course of radiotherapy had similar effects to the traditional 3-week course for early-stage breast cancer after surgery. Given these favorable results, a 5-fraction WBI regimen is appealing for many patients who wish to minimize the number of treatment visits while still reducing their risk of recurrence. Generally, tumor bed boosts further decrease the risk of recurrence, but in the setting of 5-fraction WBI, a more traditional sequential boost technique is utilized.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss your specific medications with the trial team to ensure they won't interfere with the study.
Is the radiotherapy treatment for early-stage breast cancer safe?
Research shows that this type of radiotherapy, which involves giving higher doses over a shorter period, is generally safe for early-stage breast cancer patients. Studies have looked at the side effects and found them to be manageable, with some patients experiencing mild to moderate side effects.12345
How is the radiotherapy treatment for early-stage breast cancer different from other treatments?
What data supports the effectiveness of the treatment Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for early-stage breast cancer?
Who Is on the Research Team?
Dana Casey, MD
Principal Investigator
UNC Lineberger Comprehensive Cancer Center
Are You a Good Fit for This Trial?
This trial is for individuals with early-stage breast cancer or ductal carcinoma in situ who have undergone surgery. It's designed to test a short, 5-session radiation therapy that includes a simultaneous boost to the tumor bed, aiming to reduce treatment time and recurrence risk.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive 5-fraction whole breast irradiation with a simultaneous integrated boost
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost
Find a Clinic Near You
Who Is Running the Clinical Trial?
UNC Lineberger Comprehensive Cancer Center
Lead Sponsor